An observational study in Open Angle Glaucoma (OAG) and Ocular Hypertension (OHT), sponsored by Glaukos Corporation. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Glaukos Corporation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Glaucoma, Open-Angle by Glaukos Corporation — 7 open to participants now, 10 under way, 2 of them phase 3. Glaucoma, Open-Angle · Glaukos Corporation.
Among the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, this one is one of 2 that started in 2026, is one of 5 observational ones, and was the 43rd registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →7 of the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation are open now, in 1 country. Recruiting first, the newest first:
Glaukos Corporation · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 45+
Glaukos Corporation · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 101 across 184 observational studies indexed under Glaucoma, Open-Angle.
Median enrollment 111 across the 38 interventional studies, 108 across the 5 observational. Of the 30 that completed or were terminated, 8 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
2 of the studies in Glaucoma, Open-Angle by Glaukos Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07816692Glaukos CorporationiDose TR Administration in an Office-Based Surgery Setting | 2027-03 |
| NCT06066645Glaukos CorporationTravoprost Intraocular Implant + iStent Infinite | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.
This study is a multicenter, single arm, open-label trial in adult subjects with open-angle glaucoma or ocular hypertension. The objective of the study is to assess the safety profile of iDose TR administration in an office-based surgery setting.
Adults 18 years of age or older with open-angle glaucoma or ocular hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Travoprost Intracameral Implant
Combination Product: iDose TR (travoprost intracameral implant) 75 µg
Travoprost-releasing implant preloaded in a sterile, single-use inserter.
Also known as: iDose TR
Successful administration of iDose TR in an office-based surgical setting.
Number of subjects that received iDose TR in an office-based surgical setting by the Investigator.
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Mar 2027, 10 months after the start.
Of 53 observational studies under Glaucoma, Open-Angle, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.